Pharmaceutical Industry Articles & Reports - Page 9

Examine Phase 2/3 trial results for TAK-881, a 20% SCIG therapy for primary immunodeficiency offering comparable IgG exposure in half the infusion volume.

Comprehensive guide to GxP environmental monitoring systems (EMS) for small biotech. Review FDA 21 CFR Part 11, EU GMP Annex 1, and vendor selection criteria.

An analysis of the May 2026 FDA label expansion for Vyvgart (efgartigimod) in generalized myasthenia gravis, covering triple seronegative subtypes and markets.

Analyze the BeOne-Huahui licensing agreement for the HH160 PD-1/CTLA-4/VEGF trispecific antibody. Review recent China biotech cross-border licensing trends.

Examine BioNTech's 2026 restructuring toward oncology amid declining COVID-19 vaccine revenues, and explore post-pandemic Big Pharma pipeline strategies.

Examine Merck's 2026 restructuring and 8% workforce reduction. Understand how the company utilizes AI and M&A to navigate the $300B pharma patent cliff.

Compare leading AI HCP engagement platforms for pharma commercial operations. Review the 2026 capabilities of Aktana, OptimizeRx, Pega, and Veeva Vault CRM.

Analyze how AI clinical trial recruitment addresses enrollment bottlenecks. This report examines Iterative Health's $77M expansion into cardiology and obesity.

Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.

Analyze Pfizer's $10B acquisition of Metsera and the evolving GLP-1 obesity drug market. Learn about competing pipelines, clinical data, and pharma strategy.

Analyze the 2026 FDA Accelerated AI Pathway Pilot. Review the regulatory framework and the 10 selected companies advancing AI-discovered drugs to Phase I.

Review the FDA approval of relacorilant (Lifyorli) for platinum-resistant ovarian cancer. Learn its clinical efficacy and mechanism as a GR antagonist.

Examine how AI-driven ultra-large virtual screening evaluated 325 billion molecules to identify MDL-4102, a highly selective BRD4 inhibitor for oncology.

Review the 2026 FDA approval of Optune Pax (TTFields) for locally advanced pancreatic cancer. Explore PANOVA-3 trial survival data and mechanism of action.

Examine how leading pharmaceutical companies utilize AI training and workforce upskilling programs to address digital skill gaps in drug discovery operations.

Analyze 2027 drug patent expirations and the impending patent cliff. Review a detailed loss-of-exclusivity (LOE) calendar for biologics and small molecules.

Examine LLM security risks in pharma, including prompt injection and data exfiltration. Review red teaming methods and GxP risk assessments for regulated AI.

Examine the 2026 FDA real-time clinical trial pilot. This report analyzes how AI and cloud platforms enable continuous oncology data monitoring for new drugs.

Examine the May 2026 White House MFN drug pricing policy. Learn how 17 bilateral pharma agreements and the TrumpRx initiative project $529B in U.S. savings.

Learn about the FDA's new HALO platform and Elsa 4.0 AI system. This guide covers consolidated eCTD submissions, AI review workflows, and sponsor migration.

Examine the April 2026 FDA approval of Idvynso (doravirine/islatravir). Understand this tenofovir-free, two-drug HIV regimen's clinical efficacy and safety.

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

Review AstraZeneca's tozorakimab Phase 3 MIRANDA trial results for COPD. This analysis explains IL-33 pathway biology and compares itepekimab clinical data.

Review this educational playbook for Veeva CRM Approved Email implementation. Learn about technical setup, compliance frameworks, HCP engagement, and pitfalls.